Our systematic review suggests that albumin infusion provides clear benefits in preventing AKI, reducing PICD, and improving short-term survival in decompensated cirrhosis and ACLF, with synergistic effects when combined with vasoconstrictors in HRS-1. The gene discussed is ALB; the disease is acute kidney injury.